CDIA™ Lentivirus (HIV-1 P24) Semi-Quantitative Rapid Test Kit (DTSJZ026)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Target
HIV-1 P24 Protein
Sensitivity
1-500 ng/mL
Format
Kit
Size
10 T, 100 T
Sample
Cell culture supernatant
Intended Use
CDIA™ Lentivirus (HIV-1 P24) Semi-Quantitative Rapid Test Kit is a rapid chromatographic immunoassay for semi-quantitative detection of lentivirus titers in the supernatant of cell culture. This assay takes only 10-15 minutes, compared to the conventional re-infection based assay that takes 2-3 days.
General Description
Lentivirus vector based on the human immunodeficiency virus-1 (HIV-1) has become a promising vector for gene transfer studies. Lentiviral vectors have been shown to deliver genes toneurons, lymphocytes and macrophages, cell types that previous retrovirus vectors could not be used. Lentiviral vectors have also proven to be effective in transducing brain, liver, muscle, and retina in vivo without toxicity or immune responses. Lentivirus particles are produced from 293T cells through transient transfection of 3 or 4 plasmids that encodes for the components of the virion. Viral medium containing viral particles produced by packaging cells within 48-72 hr can be harvested. To ensure that pseudoviral medium is viable, and to control the number of copies of integrated viral constructs per target cell, the viral titer needs to be determined before proceeding with transduction experiments.
Principles of Testing
CDIA™ Lentivirus (HIV-1 P24) Semi-Quantitative Rapid Test Kit is a semi-quantitative, membrane based immunoassay for the detection of lentivirus titers. The membrane is pre-coated with anti-HIV-1 24 antibodies on the test line region. During testing, specimen reacts with the particles coated with anti-HIV-1 24 antibodies. The mixture migrates upward on the membrane by capillary action to react with anti- HIV-1 24 antibodies on the membrane and generate a colored line. The minimum detection level of this test is 1 ng/mL (T Line). When the HIV-1 P24 level in the specimen is between 1-500 ng/mL, it shows a positive correlation between the concentration of HIV-1 P24 in the specimen and the intensity of the color of the test line (T). The HIV-1 P24 concentration is semi-quantitatively determined by Color Chart (Fig 1), realizing the rapid estimation of lentivirus titer.
Keywords
Lentiviral Titer Test, lentiviral p24, Lentivirus Semi-Quantitative Rapid Test, HIV-1 P24 Protein, HIV-1 P24, lentivirus production and titration, lentiviral vectors, lentiviral vector titers, Lentivirus Titration, Lentivirus Titration Semi-Quantitative

Citations


Have you cited DTSJZ026 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Predictors of First-Time and Repeat HIV Testing Among HIV-Positive Individuals in Kenya

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Authors: De Anda, Sofia; Njoroge, Anne; Njuguna, Irene; Dunbar, Matthew D.; Abuna, Felix; Macharia, Paul; Betz, Bourke; Cherutich, Peter; Bukusi, David; Farquhar, Carey; Katz, David A.

Background: Despite a doubling of HIV testing coverage in Kenya over the past decade, approximately 2 in 10 people with HIV remained unaware of their infection in 2018. HIV testing is most effective in identifying people with undiagnosed HIV through frequent and strategic testing in populations at high risk. An assessment of testing frequency and predictors of first-time and repeat testing is critical for monitoring effectiveness of testing strategies. Methods: We conducted a cross-sectional analysis of adults aged >= 18 years who tested HIV-positive at 4 HIV testing and counseling clinics in Kenya from February 2015 to February 2016. We categorized individuals based on testing history, used Wilcoxon rank-sum tests to assess differences in intervals between the most recent and current HIV test, and used log-binomial regression to determine characteristics associated with first-time and repeat testing. Results: Among 1136 people testing HIV-positive, 336 (30%) had never tested before and 800 (70%) had, of whom 208 (26%) had previously tested positive. Among previously negative repeat testers, the median intertest interval was 414 days in key/priority populations (interquartile range = 179-1072) vs. 538 in the general population (interquartile range = 228-1299) (P = 0.09). Compared with previously negative repeat testers, being a first-time tester was associated with being age >= 40 years [vs. 18-24; adjusted risk ratio = 1.67, 95% confidence interval (CI): 1.23 to 2.26], men (vs. women; adjusted risk ratio = 1.45, 95% CI: 1.21 to 1.71), and testing through provider-initiated testing and counseling (vs. client initiated; 1.19, 95% CI: 1.00 to 1.40). Conclusions: There is a need to increase HIV testing among older individuals and men, increase testing frequency in key/priority populations, and maintain provider-initiated and facility-based testing to reach first-time testers.

Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Authors: Wang, Zhao; Kang, Dongwei; Feng, Da; Cherukupalli, Srinivasulu; Jiang, Xiangyi; Fu, Zhipeng; De Clercq, Erik; Pannecouque, Christophe; Liu, Xinyong; Zhan, Peng

To address the intractable issues of drug resistance and poor solubility, a novel series of morpholine-substituted diarylpyrimidines targeting the tolerant region I and tolerant region II of NNIBP were rationally designed by utilizing the available crystallography studies. The biological evaluation results showed that four most promising compounds (14e1, 14g1, 14g2 and 14j2) displayed excellent potency against WT HIV-1 strain with EC(50 )values ranging from 58 to 87 nM, being far more potent than NVP and comparable to ETV. Besides, some derivatives exhibited moderate activity in inhibiting the mutant HIV-1 strains. More encouragingly, 14d2 (RF = 0.4) possessed higher antiresistance profile than ETV (RF = 6.3) and K-5a2 (RF = 3.0) toward the double mutant strain F227L + V106A. The HIV-1 RT inhibition assay confirmed their binding target. The molecular docking studies were conducted and discussed in detail to rationalize the preliminary SARs. Further test indicated that morpholine could indeed promote the improvement of water solubility. Additionally, the in silico prediction of physicochemical properties and CYP enzymatic inhibitory ability were investigated to evaluate their drug-like features. (C) 2020 Elsevier Masson SAS. All rights reserved.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket